01:35 PM EST, 02/25/2025 (MT Newswires) -- Candel Therapeutics ( CADL ) shares were down over 24% in recent trading on Tuesday after the company said three of seven patients with borderline resectable pancreatic ductal adenocarcinoma, or PDAC, who received CAN-2409 were still alive at the time of data cut-off.

The phase 2 study evaluated CAN-2409 plus valacyclovir together with standard-of-care chemoradiation, followed by resection, in patients with borderline resectable PDAC, according to the company.

The data cutoff date was Feb. 20 and median overall survival after enrollment was 31.4 months in the CAN-2409 group compared with 12.5 months in the control group.

Median survival after progression was 21.2 months in the CAN-2409 arm versus 7.2 months in the control arm, Candel added.

Price: 8.28, Change: -2.68, Percent Change: -24.45